Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Change in Receivables (2025)

Kura Oncology (KURA) has disclosed Change in Receivables for 1 consecutive years, with -$27.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables changed N/A to -$27.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.7 million, a N/A change, with the full-year FY2025 number at $6.7 million, up 227.38% from a year prior.
  • Change in Receivables was -$27.1 million for Q4 2025 at Kura Oncology, down from $31.4 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $46.7 million in Q1 2025 to a low of -$44.2 million in Q2 2025.